Fibrosis clinical trials

Explore recruiting fibrosis clinical trials.

Recruiting fibrosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fibrosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patient with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis

Bulgaria, Germany, Spain, Poland, Portugal, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

Germany, Italy, Netherlands, Belgium, Sweden, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

17 β-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults with Nonalcoholic Steatohepatitis

Greece, Italy, Belgium, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease

Germany, Greece, Bulgaria, France, Denmark, Czechia +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, double-blind, placebo-controlled study on the efficacy and safety of nicotinamide in patients with liver fibrosis.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

Spain, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

Fibrosis trials by city

Fibrosis in Toronto Fibrosis in Vancouver Fibrosis in Montreal Fibrosis in Calgary Fibrosis in Edmonton Fibrosis in Ottawa Fibrosis in Winnipeg Fibrosis in Quebec City Fibrosis in Hamilton Fibrosis in Kitchener Fibrosis in London Fibrosis in Halifax Fibrosis in New York Fibrosis in Los Angeles Fibrosis in Chicago Fibrosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease